Preuss Harry G, DiFerdinando Donna, Bagchi Manashi, Bagchi Debasis
Department of Physiology, Medicine and Pathology, Georgetown University Medical Center, Washington, DC 20057, USA.
J Med. 2002;33(1-4):247-64.
Obesity is a serious health problem throughout the world. More than half of U.S. adults are overweight (61%) and more than a quarter (26%) of U.S. adults are obese. The inability of many individuals to keep their weight in check by diet and exercise has created a need for additional therapeutic means to combat obesity. Despite great effort, the pharmaceutical industry has not come up with the solution; because most weight-loss drugs to date have serious adverse effects to health and well-being. The theory that beta agonists, especially beta 3 agonists, can affect body weight and fat mass is well accepted. Ephedrine has proven time and time again that it is an effective weight loss agent through its ability to increase thermogenesis and quench appetite. However, the publicity concerning adverse reactions has led to its gradual withdrawal from use by many despite the perceived consequences of obesity. Many companies are now substituting Citrus aurantium for ephedra in their formulations. Citrus aurantium, an agent containing beta agonists, has been reported to aid in weight loss in two studies and increase thermogenesis, at least to some extent, in three studies. Colker et al. (1999) reported that in a double-blind, placebo-controlled, randomized study the subjects receiving a combination of Citrus aurantium, caffeine and St John's Wort, lost significant amounts of total body weight while on a strict diet and exercise. Those in the placebo and control groups who also were on the same restricted diet did not. However, intergroup analysis showed no statistical significance among the weight changes in the three groups. In contrast, the loss of fat mass in the test group was significantly greater compared to the placebo and control groups. Jones describes an open labeled study performed on 9 women. The subjects showed a mean of 0.94 kg lost during the first week when no product was given and 2.40 kg during the second week when a Citrus aurantium product was taken. Body weight losses were statistically greater during the second week compared to the first week. Since most clinicians would agree that the most weight loss should occur initially coinciding with a greater fluid loss during the first week, these differences are even more remarkable. Three studies reported increased metabolic rates when ingesting Citrus aurantium products, however, at least two of these studies were acute. At present, Citrus aurantium may be the best thermogenic substitute for ephedra. However, more studies are needed to establish this definitively.
肥胖是一个全球性的严重健康问题。超过一半的美国成年人超重(61%),超过四分之一(26%)的美国成年人肥胖。许多人无法通过饮食和运动控制体重,这就需要更多治疗手段来对抗肥胖。尽管付出了巨大努力,制药行业仍未找到解决方案;因为迄今为止,大多数减肥药对健康和幸福都有严重的副作用。β激动剂,尤其是β3激动剂,能够影响体重和脂肪量的理论已被广泛接受。麻黄碱一次又一次地证明,它通过增加产热和抑制食欲,是一种有效的减肥药物。然而,尽管肥胖会带来种种后果,但有关不良反应的宣传导致许多人逐渐不再使用它。现在许多公司在其配方中用枳实替代麻黄。枳实是一种含有β激动剂的药物,在两项研究中被报道有助于减肥,在三项研究中至少在一定程度上能增加产热。科尔克等人(1999年)报告说,在一项双盲、安慰剂对照、随机研究中,接受枳实、咖啡因和圣约翰草组合的受试者,在严格的饮食和运动条件下,总体重显著下降。而处于同样严格饮食的安慰剂组和对照组则没有。然而,组间分析显示三组体重变化之间没有统计学意义。相比之下,试验组的脂肪量减少明显大于安慰剂组和对照组。琼斯描述了一项对9名女性进行的开放标签研究。受试者在未服用任何产品的第一周平均减重0.94千克,在服用枳实产品的第二周平均减重2.40千克。与第一周相比第二周的体重减轻具有统计学意义。由于大多数临床医生都认为最初体重减轻最多,且第一周会伴随更多的体液流失,所以这些差异更加显著。三项研究报告称,摄入枳实产品时代谢率会提高,然而,这些研究中至少有两项是急性研究。目前,枳实可能是麻黄的最佳产热替代品。然而,需要更多研究来明确证实这一点。